Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: Analysis of two randomized, double-blind, placebo-controlled studies

Epilepsy Research

Volumn 85, Issue 1, 2009, Pages 72-80

  Rosenfeld, William E ^a   Benbadis, Selim ^b   Edrich, Pascal ^c   Tassinari, Carlo Alberto ^d   Hirsch, Edouard ^e  

^a The Comprehensive Epilepsy Care Center for Children and Adults ^*  (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UCB PHARMA   (Belgium)

^d BELLARIA HOSPITAL   (Italy)

^e UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Epileptic syndromes; Generalized tonic clonic seizures on awakening; Idiopathic generalized epilepsy; Juvenile absence epilepsy; Juvenile myoclonic epilepsy; Levetiracetam

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; LAMOTRIGINE; PLACEBO; TOPIRAMATE; VALPROIC ACID;

ABSENCE; ADD ON THERAPY; ADJUVANT THERAPY; ADOLESCENT; ADULT; AGED; AGGRESSION; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENERALIZED EPILEPSY; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYOCLONUS EPILEPSY; ONSET AGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SOMNOLENCE; TONIC CLONIC SEIZURE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EPILEPSY, ABSENCE; EPILEPSY, GENERALIZED; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCLONIC EPILEPSY, JUVENILE; PIRACETAM; YOUNG ADULT;

EID: 67349156067     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2009.02.016     Document Type: Article

References (50)

1. Andermann F., and Berkovic S.F. Idiopathic generalized epilepsy with generalized and other seizures in adolescence. Epilepsia 42 (2001) 317-320
2. Beghi M., Beghi E., Cornaggia C.M., and Gobbi G. Idiopathic generalized epilepsies of adolescence. Epilepsia 47 Suppl. 2 (2006) 107-110
3. Ben-Menachem E., and Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia 41 (2000) 1276-1283
4. Benbadis S.R., Tatum W.O., and Gieron M. Idiopathic generalized epilepsy and choice of antiepileptic drugs. Neurology 61 (2003) 1793-1795
5. Benbadis S.R. Practical management issues for idiopathic generalized epilepsies. Epilepsia 46 Suppl. 9 (2005) 125-132
6. Bergey G.K. Evidence-based treatment of idiopathic generalized epilepsies with new antiepileptic drugs. Epilepsia 46 Suppl. 9 (2005) 161-168
7. Berkovic S.F., Knowlton R.C., Leroy R.F., Schiemann J., and Falter U. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Levetiracetam N01057 Study Group. Neurology 69 (2007) 1751-1760
8. Biraben A., Allain H., Scarabin J.M., Schuck S., and Edan G. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology 55 (2000) 1757-1758
9. Biton V., Montouris G.D., Ritter F., Riviello J.J., Reife R., Lim P., and Pledger G. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology 52 (1999) 1330-1337
10. Biton V., Sackellares J.C., Vuong A., Hammer A.E., Barrett P.S., and Messenheimer J.A. Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology 65 (2005) 1737-1743
11. Boon P., Chauvel P., Pohlmann-Eden B., Otoul C., and Wroe S. Dose-response effect of levetiracetam 1000 and 2000 mg/day in partial epilepsy. Epilepsy Res. 48 (2002) 77-89
12. Brodie M.J., Perucca E., Ryvlin P., Ben-Menachem E., and Meencke H.J. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 68 (2007) 402-408
13. Cereghino J.J., Biton V., Abou-Khalil B., Dreifuss F., Gauer L.J., and Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 55 (2000) 236-242
14. Crespel A., Genton P., Berramdane M., Coubes P., Monicard C., Baldy-Moulinier M., and Gelisse P. Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies. Neurology 65 (2005) 762-764
15. Engel Jr. J. ILAE classification of epilepsy syndromes. Epilepsy Res. 70 Suppl. 1 (2006) S5-10
16. Fountain N.B., Conry J.A., Rodríguez-Leyva I., Gutierrez-Moctezuma J., Salas E., Coupez R., Stockis A., and Lu Z.S. Prospective assessment of levetiracetam pharmacokinetics during dose escalation in 4- to 12-year-old children with partial-onset seizures on concomitant carbamazepine or valproate. Epilepsy Res. 74 (2007) 60-69
17. Gelisse P., Genton P., Kuate C., Pesenti A., Baldy-Moulinier M., and Crespel A. Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies. Epilepsia 45 (2004) 1282-1286
18. Genton P., Gelisse P., Thomas P., and Dravet C. Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy?. Neurology 55 (2000) 1106-1109
19. Genton P., Gelisse P., and Crespel A. Lack of efficacy and potential aggravation of myoclonus with lamotrigine in Unverricht-Lundborg disease. Epilepsia 47 (2006) 2083-2085
20. Gilliam F., Steinhoff B.J., Bittermann H.J., Kuzniecky R., Faught E., and Abou-Khalil B. Adult myoclonic epilepsy: a distinct syndrome of idiopathic generalized epilepsy. Neurology 55 (2000) 1030-1033
21. Glauser T.A., Ayala R., Elterman R.D., Mitchell W.G., Van Orman C.B., Gauer L.J., and Lu Z. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology 66 (2006) 1654-1660
22. Grosso S., Franzoni E., Coppola G., Iannetti P., Verrotti A., Cordelli D.M., Marchiani V., Pascotto A., Spalice A., Acampora B., Morgese G., and Balestri P. Efficacy and safety of levetiracetam: an add-on trial in children with refractory epilepsy. Seizure 14 (2005) 248-253
23. Huppertz H.-J., Feuerstein T., and Schulze-Bonhage A. Myoclonus in epilepsy patients with anticonvulsive add-on therapy with pregabalin. Epilepsia 42 (2001) 790-792
24. ILAE, 1981. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 22, 489-501.
25. ILAE, 1989. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 30, 389-399.
26. Jallon P., and Latour P. Epidemiology of idiopathic generalized epilepsies. Epilepsia 46 Suppl. 9 (2005) 10-14
27. Kaminski R.M., Matagne A., Leclercq K., Gillard M., Michel P., Kenda B., Talaga P., and Klitgaard H. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology 54 (2008) 715-720
28. Knake S., Hamer H.M., Schomburg U., Oertel W.H., and Rosenow F. Tiagabine-induced absence status in idiopathic generalized epilepsy. Seizure 8 (1999) 314-317
29. Krauss G.L., Betts T., Abou-Khalil B., Gergey G., Yarrow H., and Miller A. Levetiracetam treatment of idiopathic generalised epilepsy. Seizure 12 (2003) 617-620
30. Labate A., Colosimo E., Gambardella A., Leggio U., Ambrosio R., and Quattrone A. Levetiracetam in patients with generalised epilepsy and myoclonic seizures: an open label study. Seizure 15 (2006) 214-218
31. Lagae L., Buyse G., and Ceulemans B. Clinical experience with levetiracetam in childhood epilepsy: an add-on and mono-therapy trial. Seizure 14 (2005) 66-71
32. Lippmann S.M., Montouris G.D., Rosenfeld W.E., and Schaefer P.A. Levetiracetam-a helpful new drug. Epilepsia 43 Suppl. 7 (2002) 295
33. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., and Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 9861-9866
34. Margineanu D.-G., and Klitgaard H. Levetiracetam mechanism of action in antiepileptic drugs. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). Antiepileptic Drugs. 5th ed. (2002), Lippincott Williams & Wilkins, Philadelphia 419-427
35. Mattson R.H. Overview: idiopathic generalized epilepsies. Epilepsia 44 Suppl. 2 (2003) 2-6
36. Niklson I., Edrich P., and Verdru P. Identifying baseline characteristics of placebo responders versus non-responders in randomized double-blind trials of refractory partial-onset seizures. Epileptic Disord. 8 (2006) 37-44
37. Noachtar S., Andermann E., Meyvisch P., Andermann F., Gough W.B., and Schiemann Delgado J. N166 levetiracetam study group Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 70 (2008) 607-616
38. Nordli Jr. D.R. Idiopathic generalized epilepsies recognized by the International League Against Epilepsy. Epilepsia 46 Suppl. 9 (2005) 48-56
39. Patsalos P.N. Clinical pharmacokinetics of levetiracetam. Clin. Pharmacokinet. 43 (2004) 707-724
40. Pellock J.M., Glauser T.A., Bebin E.M., Fountain N.B., Ritter F.J., Coupez R.M., and Shields W.D. Pharmacokinetic study of levetiracetam in children. Epilepsia 42 (2001) 1574-1579
41. Perucca E. Birth defects after prenatal exposure to antiepileptic drugs. Lancet Neurol. 4 (2005) 781-786
42. Reutens D.C., and Berkovic S.F. Idiopathic generalized epilepsy of adolescence: are the syndromes clinically distinct?. Neurology 45 (1995) 1469-1476
43. Rheims S., Cucherat M., Arzimanoglou A., and Ryvlin P. Greater response to placebo in children than in adults: a systematic review and meta-analysis in drug-resistant partial epilepsy. PLoS Med. 5 (2008) e166
44. Rocamora R., Wagner K., and Schulze-Bonhage A. Levetiracetam reduces frequency and duration of epileptic activity in patients with refractory primary generalized epilepsy. Seizure 15 (2006) 428-433
45. Shorvon S.D., Lowenthal A., Janz D., Bielen E., and Loiseau P. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia 41 (2000) 1179-1186
46. Skardoutsou A., Voudris K.A., and Vagiakou E.A. Non-convulsive status epilepticus associated with tiagabine therapy in children. Seizure 12 (2003) 599-601
47. Specchio L.M., Gambardella A., Giallonardo A.T., Michelucci R., Specchio N., Boero G., and La N.A. Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy. Epilepsy Res. 71 (2006) 32-39
48. Thomas P., Valton L., and Genton P. Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy. Brain 129 (2006) 1281-1292
49. Van Elteren P. On the combination of independent two sample tests of Wilcoxon. Bull. Inst. Ins. Stat. 37 (1960) 351
50. Yenjun S., Harvey A.S., Marini C., Newton M.R., King M.A., and Berkovic S.F. EEG in adult-onset idiopathic generalized epilepsy. Epilepsia 44 (2003) 252-256